6dc0
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6dc0' size='340' side='right'caption='[[6dc0]], [[Resolution|resolution]] 2.80Å' scene=''> | <StructureSection load='6dc0' size='340' side='right'caption='[[6dc0]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[6dc0]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[6dc0]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DC0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6DC0 FirstGlance]. <br> |
- | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8Å</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6dc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dc0 OCA], [https://pdbe.org/6dc0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6dc0 RCSB], [https://www.ebi.ac.uk/pdbsum/6dc0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6dc0 ProSAT]</span></td></tr> |
</table> | </table> | ||
+ | == Disease == | ||
+ | [https://www.uniprot.org/uniprot/CEBPA_HUMAN CEBPA_HUMAN] Acute myeloid leukemia with CEBPA somatic mutations;Acute myeloid leukemia with t(8;21)(q22;q22) translocation;Inherited acute myeloid leukemia. The disease is caused by variants affecting the gene represented in this entry. | ||
== Function == | == Function == | ||
- | [[ | + | [https://www.uniprot.org/uniprot/CEBPA_HUMAN CEBPA_HUMAN] Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Down-regulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity).[UniProtKB:P05554][UniProtKB:P53566]<ref>PMID:11242107</ref> <ref>PMID:14660596</ref> Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation (PubMed:14660596).[UniProtKB:P05554][UniProtKB:P53566]<ref>PMID:14660596</ref> Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation.<ref>PMID:20075868</ref> [https://www.uniprot.org/uniprot/TRIB1_HUMAN TRIB1_HUMAN] Interacts with MAPK kinases and regulates activation of MAP kinases. May not display kinase activity.<ref>PMID:15299019</ref> <ref>PMID:15299019</ref> |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 22: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Brewster | + | [[Category: Brewster JL]] |
- | [[Category: Jamieson | + | [[Category: Jamieson SA]] |
- | [[Category: Mace | + | [[Category: Mace PD]] |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Tribbles (TRIB1) pseudokinase fused to CCAAT-enhancer binding protein (C/EBPalpha) degron
|